-
Three class 1 new drugs + PD-L1 approved clinical, Hengrui pharmaceutical R & D strength to reach a new high
Time of Update: 2017-12-19
Excellent content on December 14, Hengrui pharmaceutical announced that the company and its subsidiaries Shanghai Hengrui, Jiangsu Shengdi and Chengdu Shengdi have recently received the approval opini
-
4 billion varieties "pass" consistency evaluation! Is the Yangtze River not fast enough for this pharmaceutical company?
Time of Update: 2017-12-18
Highlights recently, CFDA food and drug audit and Inspection Center (CFDI) released the news of the first batch of consistency evaluation varieties due to on-site inspection work, with securities comp
-
289 what products will be eliminated naturally?
Time of Update: 2017-12-18
Recently, the office of quality and efficacy consistency evaluation of generic drugs launched the column of quality and efficacy consistency evaluation of generic drugs on CDE website and released the
-
60 billion anti-tumor drugs market, the first imitation of "Xinwei" is expected to further rush
Time of Update: 2017-12-13
Recently, CFDA food and drug audit and Inspection Center released the work trend, saying that the first batch of generic drug conformity assessment varieties had been started due to on-site inspection
-
Chinese patent medicine market trapped: low growth rate, three top 10 varieties decline
Time of Update: 2017-12-12
Recently, the State Food and Drug Administration issued the circular on the issuance of technical guidelines for the naming of generic names of Chinese patent medicines and the circular on the standar
-
The total sales of the four neurosystemic drugs exceeded 5 billion yuan. Who can get through the red line of consistency evaluation in the first batch?
Time of Update: 2017-12-12
Highlights on November 29, the news that the first batch of generic drug conformity evaluation varieties were started due to the on-site inspection attracted the attention of the industry Some securit
-
Can levetiracetam take the lead in the 4 billion antiepileptic terminal market and pass the consistency evaluation?
Time of Update: 2017-12-11
Wonderful content: previously, due to the lack of consistency evaluation mechanism, some generic drugs in China have been far behind the original drugs for a long time Especially for the elderly, the
-
This year, the first batch of domestic varieties will usher in generic competition!
Time of Update: 2017-12-08
As of December 7 this year, a total of 45 varieties have been approved for the first time in China In recent years, CFDA has become more and more strict with the drug review and approval system, and t
-
Hengrui has a wide distribution, and the application data of Zhengda Tianqing and dongyanghua drugs in Category 1 & new category 4 are eye-catching: analysis of drug registration trend in 2017
Time of Update: 2017-12-08
2017 is about to pass With the in-depth implementation of drug registration reform, what is the change of enterprise declaration strategy?
Which varieties are more popular?
-
Pfizer, Xi'an YANGSEN and Xinji are challenged! Within three days, 3 local pharmaceutical companies were listed on the blockbuster, and local innovation was officially on the rise.
Time of Update: 2017-12-06
Within three days, three local enterprises have been approved of the heavyweight new drugs For a group of local enterprises, including Cohen, Shuanglu and hausen, this is undoubtedly an important retu
-
Clopidogrel to meet the fierce enemy: the new antithrombotic "heavy bomb" has grown by more than 60% in China, and the first generic drug will be approved soon!
Time of Update: 2017-12-06
CDE recently released the public list of the 24th batch of drug registration applications to be included in the priority review process, among which tegrilol and tablets of xinlitai are listed as the
-
The market of anti ed drugs has broken through 10 billion scale, and Jinge and Viagra are equally divided
Time of Update: 2017-12-05
Recently, sildenafil citrate tablets developed by Changshan Pharmaceutical Co., Ltd were officially approved by CFDA for production registration Since Pfizer's Viagra entered the country in 1998, ther
-
The global position of China's antibody drugs: not only in quantity, but also in innovation!
Time of Update: 2017-12-05
All over the world, biological drugs, especially antibody drugs, have begun to break out their vitality after years of basic research and technology accumulation, and become the most dynamic and promi
-
In the past ten years, China's "magic medicine" has finally come into the market, snapping up the global 10 billion market!
Time of Update: 2017-12-05
Wonderful content on December 2, Shuanglu pharmaceutical industry announced that it had received the new drug certificate and drug registration approval document of lenalidomide approved and issued by
-
Development and patent progress of CDK4 / 6 inhibitors in more than 20 domestic companies
Time of Update: 2017-12-02
Two days ago, an article entitled "two nature confirmed that this kind of heavy-duty anticancer drugs can make cancer immunotherapy change" cattle ", wrote that in August this year, a study on nature
-
AIDS global market is about to break 30 billion US dollars, and domestic enterprises are scrambling for food
Time of Update: 2017-12-01
The highlight of this year's event is December 1, which coincides with the 30th World AIDS Day The theme of this year's publicity is "sharing the responsibility of AIDS prevention, sharing the right t
-
Over 7 billion yuan of peptic ulcer retail market, 39% of which are gastric proton pump inhibitors
Time of Update: 2017-11-30
Peptic ulcer (PU) refers to the inflammatory reaction and necrotic lesion of mucosa under the action of various pathogenic factors The lesion reaches to the muscularis of mucosa and often occurs in th
-
Interpretation of the first batch of catalogues of listed chemical drugs in China, 15 product regulations of 10 Chinese pharmaceutical companies including Hengrui, Qilu, Chipset, Hausen, and Livzon were shortlisted
Time of Update: 2017-11-30
On November 28, 2017, CDE issued a notice on Soliciting Opinions on the first batch of varieties included in the catalogue of Chinese listed chemicals Solicit opinions from the public, and the deadlin
-
First in China! PCSK9 McAb, the most popular lipid-lowering drug in Junshi biology, has entered phase I clinical practice
Time of Update: 2017-11-28
Recently, the author found a piece of information on "drug clinical trial registration and information publicity platform", as follows: the first publicity date of this information is November 17, 201
-
Stunned! In the first three quarters, this pharmaceutical company invested nearly 1.5 billion in R & D, with 28 varieties exceeding 100 million
Time of Update: 2017-11-27
Highlights: a few days ago, China biopharmaceutical announced its results in the first three quarters of 2017, with an operating revenue of 11.447 billion yuan, a year-on-year increase of 9.5%; R & D
